“Time Off for Clinical Trials," launched on Nov. 20, sees six of BioNJ’s biggest members—Amicus Therapeutics, Bristol Myers ...

Alzheimer’s and Huntington’s patients do have different symptoms and disease biology, but that made no difference to the ...

No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...

Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third ...

Lindus Health has gone all-in on all-in-one CRO offerings. Less than a month after launching its All-in-One Women's Health ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, ...